MRK
insider transactionsMerck & Co., Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
No open-market buys or sells this period. The trades below are grants, option exercises and gifts, which carry no market price.
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
—
16.9K sh
Own +956%
-
Grant·A
Director
$220.0K
1.9K sh · $118.72
Own +12%
-
Grant·A
Director
$220.0K
1.9K sh · $118.72
Own +7%
-
Grant·A
Director
$220.0K
1.9K sh · $118.72
Own +10%
-
Grant·A
Director
$220.0K
1.9K sh · $118.72
Own +3%
-
Grant·A
Director
$220.0K
1.9K sh · $118.72
Own +6%
-
Grant·A
Director
$220.0K
1.9K sh · $118.72
Own +14%
-
Grant·A
Director
$220.0K
1.9K sh · $118.72
Own +12%
-
Grant·A
Director
$220.0K
1.9K sh · $118.72
Own +52%
-
Grant·A
Director
$220.0K
1.9K sh · $118.72
Own +6%
-
Grant·A
Director
$220.0K
1.9K sh · $118.72
Own +6%
-
Grant·A
Director
$220.0K
1.9K sh · $118.72
Own +19%
-
Grant·A
Director
$0
1.2K sh
Own +16%
-
Grant·A
Director
$200.0K
1.6K sh · $124.87
Own +13%
-
Grant·A
EVP, General Counsel
$0
35.3K sh
Own New
-
Grant·A
EVP, General Counsel
$0
12.1K sh
Own New
-
Grant·A
EVP,Chief Info&Digital Officer
$0
13.6K sh
Own New
-
Grant·A
EVP,Chief Info&Digital Officer
$0
4.6K sh
Own New
-
Grant·A
EVP, Oncology & Int?l
$0
31.0K sh
Own New
-
Grant·A
EVP, Oncology & Int?l
$0
10.6K sh
Own New
-
Grant·A
SVP Fin. - Global Controller
$0
5.0K sh
Own New
-
Grant·A
SVP Fin. - Global Controller
$0
2.3K sh
Own New
-
Grant·A
EVP & Pres. MMD
$0
21.7K sh
Own New
-
Grant·A
EVP & Pres. MMD
$0
7.4K sh
Own New
-
Grant·A
EVP & CFO
$0
46.6K sh
Own New
-
Grant·A
EVP & CFO
$0
15.9K sh
Own New
-
Grant·A
Dean Y Li KEY
Executive VP & President, MRL
$0
58.2K sh
Own New
-
Grant·A
Dean Y Li KEY
Executive VP & President, MRL
$0
19.9K sh
Own New
-
Grant·A
EVP, Chief HR Officer
$0
23.3K sh
Own New
-
Grant·A
EVP, Chief HR Officer
$0
8.0K sh
Own New
-
Grant·A
EVP, Access, Policy & Comms
$0
19.4K sh
Own New
-
Grant·A
EVP, Access, Policy & Comms
$0
6.6K sh
Own New
-
Grant·A
EVP, Specialty, Pharma, & ID
$0
31.0K sh
Own New
-
Grant·A
EVP, Specialty, Pharma, & ID
$0
35.4K sh
Own New
-
Grant·A
EVP, Specialty, Pharma, & ID
$0
10.6K sh
Own New
-
Grant·A
EVP&Pres, Merck Animal Heallth
$0
34.9K sh
Own New
-
Grant·A
EVP&Pres, Merck Animal Heallth
$0
11.9K sh
Own New
-
Grant·A
Robert M Davis KEY
Chairman, CEO & President
$0
139.7K sh
Own New
-
Grant·A
Robert M Davis KEY
Chairman, CEO & President
$0
47.7K sh
Own New
-
Exercise·M
SVP Fin. - Global Controller
$0
383 sh
Own New
-
Other·F
SVP Fin. - Global Controller
$14.8K
132 sh · $112.16
Own -1%
-
Exercise·M
SVP Fin. - Global Controller
$43.0K
383 sh · $112.16
Own +4%
-
Exercise·M
EVP & Pres. MMD
$0
552 sh
Own New
-
Other·F
EVP & Pres. MMD
$17.8K
159 sh · $112.16
Own -1%
-
Exercise·M
EVP & Pres. MMD
$61.9K
552 sh · $112.16
Own +3%
-
Exercise·M
SVP Fin. - Global Controller
$0
464 sh
Own +46400%
-
Other·F
SVP Fin. - Global Controller
$17.6K
159 sh · $110.95
Own -2%
-
Exercise·M
SVP Fin. - Global Controller
$51.5K
464 sh · $110.95
Own +5%
-
Exercise·M
EVP, Chief HR Officer
$0
11.3K sh
Own New
-
Other·F
EVP, Chief HR Officer
$570.6K
5.1K sh · $110.95
Own -27%
-
Exercise·M
EVP, Chief HR Officer
$1.3M
11.3K sh · $110.95
Own +150%
-
Exercise·M
EVP,Chief Info&Digital Officer
$0
1.4K sh
Own +100%
-
Other·F
EVP,Chief Info&Digital Officer
$74.7K
679 sh · $110.03
Own -2%
-
Exercise·M
EVP,Chief Info&Digital Officer
$151.5K
1.4K sh · $110.03
Own +4%
-
Exercise·M
SVP Fin. - Global Controller
$0
944 sh
Own +100%
-
Other·F
SVP Fin. - Global Controller
$35.6K
324 sh · $110.03
Own -4%
-
Exercise·M
SVP Fin. - Global Controller
$103.9K
944 sh · $110.03
Own +11%
-
Exercise·M
EVP, General Counsel
$0
3.0K sh
Own +100%
-
Other·F
EVP, General Counsel
$160.0K
1.5K sh · $110.03
Own -2%
-
Exercise·M
EVP, General Counsel
$324.7K
3.0K sh · $110.03
Own +4%
-
Exercise·M
EVP, Oncology & Int?l
$0
1.4K sh
Own +100%
-
Other·F
EVP, Oncology & Int?l
$74.7K
679 sh · $110.03
Own -3%
-
Exercise·M
EVP, Oncology & Int?l
$151.5K
1.4K sh · $110.03
Own +6%
-
Exercise·M
EVP & CFO
$0
3.9K sh
Own +100%
-
Other·F
EVP & CFO
$213.2K
1.9K sh · $110.03
Own -2%
-
Exercise·M
EVP & CFO
$433.0K
3.9K sh · $110.03
Own +4%
-
Exercise·M
Dean Y Li KEY
Executive VP & President, MRL
$0
4.7K sh
Own +100%
-
Other·F
Dean Y Li KEY
Executive VP & President, MRL
$255.9K
2.3K sh · $110.03
Own -2%
-
Exercise·M
Dean Y Li KEY
Executive VP & President, MRL
$519.6K
4.7K sh · $110.03
Own +5%
-
Exercise·M
EVP, Chief HR Officer
$0
2.1K sh
Own +100%
-
Other·F
EVP, Chief HR Officer
$78.7K
715 sh · $110.03
Own -9%
-
Exercise·M
EVP, Chief HR Officer
$229.4K
2.1K sh · $110.03
Own +34%
-
Exercise·M
EVP, Access, Policy & Comms
$0
2.0K sh
Own +100%
-
Other·F
EVP, Access, Policy & Comms
$106.6K
969 sh · $110.03
Own -2%
-
Exercise·M
EVP, Access, Policy & Comms
$216.4K
2.0K sh · $110.03
Own +3%
-
Exercise·M
EVP&Pres, Merck Animal Heallth
$0
2.5K sh
Own +100%
-
Other·F
EVP&Pres, Merck Animal Heallth
$136.5K
1.2K sh · $110.03
Own -1%
-
Exercise·M
EVP&Pres, Merck Animal Heallth
$277.1K
2.5K sh · $110.03
Own +2%
-
Exercise·M
Robert M Davis KEY
Chairman, CEO & President
$0
13.3K sh
Own +100%
-
Other·F
Robert M Davis KEY
Chairman, CEO & President
$720.8K
6.6K sh · $110.03
Own -1%
-
Exercise·M
Robert M Davis KEY
Chairman, CEO & President
$1.5M
13.3K sh · $110.03
Own +3%
-
Exercise·M
Exe V-P & Pres. MMD
$0
2.6K sh
Own +100%
-
Other·F
Exe V-P & Pres. MMD
$124.3K
1.1K sh · $110.03
Own -7%
-
Exercise·M
Exe V-P & Pres. MMD
$285.7K
2.6K sh · $110.03
Own +19%
-
Grant·A
Director
$0
4 sh
Own +0%
-
Grant·A
Director
$0
781 sh
Own +12%
-
Other·D
Director
$0
781 sh
Own -9%
-
Grant·A
Director
$0
5.1K sh
Own +80%
-
Grant·A
Director
$0
3.3K sh
Own +0%
-
Grant·A
Director
$8.1K
68 sh · $120.29
Own +0%
-
Grant·A
Director
$30.0K
249 sh · $120.29
Own +1%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 4, 2026 | Stephen Mayo | Grant A | 16.9K | — |
| May 29, 2026 | Kathy J Warden | Grant A | 1.9K | $220.0K |
| May 29, 2026 | Inge G Thulin | Grant A | 1.9K | $220.0K |
| May 29, 2026 | Christine E Seidman | Grant A | 1.9K | $220.0K |
| May 29, 2026 | Patricia F Russo | Grant A | 1.9K | $220.0K |
| May 29, 2026 | Paul Rothman | Grant A | 1.9K | $220.0K |
| May 29, 2026 | Stephen Mayo | Grant A | 1.9K | $220.0K |
| May 29, 2026 | Risa J Lavizzo-Mourey | Grant A | 1.9K | $220.0K |
| May 29, 2026 | Surendralal Lanca Karsanbhai | Grant A | 1.9K | $220.0K |
| May 29, 2026 | Pamela J. Craig | Grant A | 1.9K | $220.0K |
| May 29, 2026 | Mary Ellen Coe | Grant A | 1.9K | $220.0K |
| May 29, 2026 | Douglas M Baker JR | Grant A | 1.9K | $220.0K |
| May 8, 2026 | Pamela J. Craig | Grant A | 1.2K | $0 |
| May 7, 2026 | Robert M Davis | Grant A | 1.6K | $200.0K |
| May 5, 2026 | Jennifer Zachary | Grant A | 35.3K | $0 |
| May 5, 2026 | Jennifer Zachary | Grant A | 12.1K | $0 |
| May 5, 2026 | David Michael Williams | Grant A | 13.6K | $0 |
| May 5, 2026 | David Michael Williams | Grant A | 4.6K | $0 |
| May 5, 2026 | Johannes Jacobus Oosthuizen | Grant A | 31.0K | $0 |
| May 5, 2026 | Johannes Jacobus Oosthuizen | Grant A | 10.6K | $0 |
| May 5, 2026 | Dalton E. Smart III | Grant A | 5.0K | $0 |
| May 5, 2026 | Dalton E. Smart III | Grant A | 2.3K | $0 |
| May 5, 2026 | David R. Maraldo | Grant A | 21.7K | $0 |
| May 5, 2026 | David R. Maraldo | Grant A | 7.4K | $0 |
| May 5, 2026 | Caroline Litchfield KEY | Grant A | 46.6K | $0 |
| May 5, 2026 | Caroline Litchfield KEY | Grant A | 15.9K | $0 |
| May 5, 2026 | Dean Y Li KEY | Grant A | 58.2K | $0 |
| May 5, 2026 | Dean Y Li KEY | Grant A | 19.9K | $0 |
| May 5, 2026 | Betty D Larson | Grant A | 23.3K | $0 |
| May 5, 2026 | Betty D Larson | Grant A | 8.0K | $0 |
| May 5, 2026 | Chirfi Guindo | Grant A | 19.4K | $0 |
| May 5, 2026 | Chirfi Guindo | Grant A | 6.6K | $0 |
| May 5, 2026 | Brian Foard | Grant A | 31.0K | $0 |
| May 5, 2026 | Brian Foard | Grant A | 35.4K | $0 |
| May 5, 2026 | Brian Foard | Grant A | 10.6K | $0 |
| May 5, 2026 | Richard R. Deluca | Grant A | 34.9K | $0 |
| May 5, 2026 | Richard R. Deluca | Grant A | 11.9K | $0 |
| May 5, 2026 | Robert M Davis KEY | Grant A | 139.7K | $0 |
| May 5, 2026 | Robert M Davis KEY | Grant A | 47.7K | $0 |
| May 2, 2026 | Dalton E. Smart III | Exercise M | 383 | $0 |
| May 2, 2026 | Dalton E. Smart III | Other F | 132 | $14.8K |
| May 2, 2026 | Dalton E. Smart III | Exercise M | 383 | $43.0K |
| May 2, 2026 | David R. Maraldo | Exercise M | 552 | $0 |
| May 2, 2026 | David R. Maraldo | Other F | 159 | $17.8K |
| May 2, 2026 | David R. Maraldo | Exercise M | 552 | $61.9K |
| Apr 30, 2026 | Dalton E. Smart III | Exercise M | 464 | $0 |
| Apr 30, 2026 | Dalton E. Smart III | Other F | 159 | $17.6K |
| Apr 30, 2026 | Dalton E. Smart III | Exercise M | 464 | $51.5K |
| Apr 30, 2026 | Betty D Larson | Exercise M | 11.3K | $0 |
| Apr 30, 2026 | Betty D Larson | Other F | 5.1K | $570.6K |
| Apr 30, 2026 | Betty D Larson | Exercise M | 11.3K | $1.3M |
| Apr 29, 2026 | David Michael Williams | Exercise M | 1.4K | $0 |
| Apr 29, 2026 | David Michael Williams | Other F | 679 | $74.7K |
| Apr 29, 2026 | David Michael Williams | Exercise M | 1.4K | $151.5K |
| Apr 29, 2026 | Dalton E. Smart III | Exercise M | 944 | $0 |
| Apr 29, 2026 | Dalton E. Smart III | Other F | 324 | $35.6K |
| Apr 29, 2026 | Dalton E. Smart III | Exercise M | 944 | $103.9K |
| Apr 29, 2026 | Jennifer Zachary | Exercise M | 3.0K | $0 |
| Apr 29, 2026 | Jennifer Zachary | Other F | 1.5K | $160.0K |
| Apr 29, 2026 | Jennifer Zachary | Exercise M | 3.0K | $324.7K |
| Apr 29, 2026 | Johannes Jacobus Oosthuizen | Exercise M | 1.4K | $0 |
| Apr 29, 2026 | Johannes Jacobus Oosthuizen | Other F | 679 | $74.7K |
| Apr 29, 2026 | Johannes Jacobus Oosthuizen | Exercise M | 1.4K | $151.5K |
| Apr 29, 2026 | Caroline Litchfield KEY | Exercise M | 3.9K | $0 |
| Apr 29, 2026 | Caroline Litchfield KEY | Other F | 1.9K | $213.2K |
| Apr 29, 2026 | Caroline Litchfield KEY | Exercise M | 3.9K | $433.0K |
| Apr 29, 2026 | Dean Y Li KEY | Exercise M | 4.7K | $0 |
| Apr 29, 2026 | Dean Y Li KEY | Other F | 2.3K | $255.9K |
| Apr 29, 2026 | Dean Y Li KEY | Exercise M | 4.7K | $519.6K |
| Apr 29, 2026 | Betty D Larson | Exercise M | 2.1K | $0 |
| Apr 29, 2026 | Betty D Larson | Other F | 715 | $78.7K |
| Apr 29, 2026 | Betty D Larson | Exercise M | 2.1K | $229.4K |
| Apr 29, 2026 | Chirfi Guindo | Exercise M | 2.0K | $0 |
| Apr 29, 2026 | Chirfi Guindo | Other F | 969 | $106.6K |
| Apr 29, 2026 | Chirfi Guindo | Exercise M | 2.0K | $216.4K |
| Apr 29, 2026 | Richard R. Deluca | Exercise M | 2.5K | $0 |
| Apr 29, 2026 | Richard R. Deluca | Other F | 1.2K | $136.5K |
| Apr 29, 2026 | Richard R. Deluca | Exercise M | 2.5K | $277.1K |
| Apr 29, 2026 | Robert M Davis KEY | Exercise M | 13.3K | $0 |
| Apr 29, 2026 | Robert M Davis KEY | Other F | 6.6K | $720.8K |
| Apr 29, 2026 | Robert M Davis KEY | Exercise M | 13.3K | $1.5M |
| Apr 29, 2026 | Sanat Chattopadhyay | Exercise M | 2.6K | $0 |
| Apr 29, 2026 | Sanat Chattopadhyay | Other F | 1.1K | $124.3K |
| Apr 29, 2026 | Sanat Chattopadhyay | Exercise M | 2.6K | $285.7K |
| Apr 10, 2026 | Pamela J. Craig | Grant A | 4 | $0 |
| Apr 10, 2026 | Pamela J. Craig | Grant A | 781 | $0 |
| Apr 10, 2026 | Pamela J. Craig | Other D | 781 | $0 |
| Apr 1, 2026 | Caroline Litchfield | Grant A | 5.1K | $0 |
| Apr 1, 2026 | Dean Y Li | Grant A | 3.3K | $0 |
| Mar 31, 2026 | Christine E Seidman | Grant A | 68 | $8.1K |
| Mar 31, 2026 | Mary Ellen Coe | Grant A | 249 | $30.0K |
About MRK insider trading
This page tracks insider transactions for Merck & Co., Inc. (MRK) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.